Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

455 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology.
Garrido P, Paz-Ares L, Majem M, Morán T, Trigo JM, Bosch-Barrera J, Garcίa-Campelo R, González-Larriba JL, Sánchez-Torres JM, Isla D, Viñolas N, Camps C, Insa A, Juan Ó, Massuti B, Paredes A, Artal Á, López-Brea M, Palacios J, Felip E. Garrido P, et al. Cancer Med. 2021 Sep;10(17):5878-5888. doi: 10.1002/cam4.4135. Epub 2021 Jul 23. Cancer Med. 2021. PMID: 34296539 Free PMC article. Clinical Trial.
Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
Bellmunt J, Albanell J, Paz-Ares L, Climent MA, González-Larriba JL, Carles J, de la Cruz JJ, Guillem V, Díaz-Rubio E, Cortés-Funes H, Baselga J; Spanish Oncology Genitourinary Group. Bellmunt J, et al. Cancer. 2002 Aug 15;95(4):751-7. doi: 10.1002/cncr.10762. Cancer. 2002. PMID: 12209718 Free article. Clinical Trial.
Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study.
Aparicio J, Germà JR, García del Muro X, Maroto P, Arranz JA, Sáenz A, Barnadas A, Dorca J, Gumà J, Olmos D, Bastús R, Carles J, Almenar D, Sánchez M, Paz-Ares L, Satrústegui JJ, Mellado B, Balil A, López-Brea M, Sánchez A; Second Spanish Germ Cell Cancer Cooperative Group. Aparicio J, et al. J Clin Oncol. 2005 Dec 1;23(34):8717-23. doi: 10.1200/JCO.2005.01.9810. Epub 2005 Oct 31. J Clin Oncol. 2005. PMID: 16260698 Clinical Trial.
Prognostic value of KIT expression in small cell lung cancer.
López-Martin A, Ballestín C, Garcia-Carbonero R, Castaño A, Lopez-Ríos F, López-Encuentra A, Sánchez-Cespedes M, Castellano D, Bartolomé A, Cortés-Funes H, Paz-Ares L. López-Martin A, et al. Lung Cancer. 2007 Jun;56(3):405-13. doi: 10.1016/j.lungcan.2007.01.029. Epub 2007 Apr 8. Lung Cancer. 2007. PMID: 17420067
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G, Muñoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D, Rosell R. Cobo M, et al. J Clin Oncol. 2007 Jul 1;25(19):2747-54. doi: 10.1200/JCO.2006.09.7915. J Clin Oncol. 2007. PMID: 17602080 Clinical Trial.
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, Ranade AA, Cohen G, Trigo JM, Sandler AB, Bonomi PD, Herbst RS, Krebs AD, Vasselli J, Johnson BE. Heymach JV, et al. J Clin Oncol. 2008 Nov 20;26(33):5407-15. doi: 10.1200/JCO.2008.17.3138. Epub 2008 Oct 20. J Clin Oncol. 2008. PMID: 18936474 Clinical Trial.
455 results